USPTO serial 97148593
GPCR NATIVE COMPLEX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MANGUBAT, ALEXANDER GEORGE
- Law office
- TMO LAW OFFICE 121 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with GPCR NATIVE COMPLEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Francisco, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shane Rumbaugh
Shane Rumbaugh RUMBAUGH LAW PLLC2400 ANSYS DRIVE, SUITE 102CANONSBURG, PA 15317UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for scientific research use; chemical reagents for use in genetic research | ACTIVE | — |
| 005 | Pharmaceutical preparations for modulating G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical preparations for use in neurology, endocrinology, metabolism, immunology, oncology, cardiovascular medicine, gastroenterology, pain, anesthesiology, dermatology, ophthalmology, psychiatry, pulmonology, urology, reproductive medicine, and orthopedics; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on various GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; pharmaceutical preparations for targeting GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; biological preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for use in medical research | ACTIVE | — |
| 040 | Custom manufacture of biochemical systems, namely, custom manufacture of systems for targeting G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders | ACTIVE | — |
| 042 | Bio-technology and scientific services, namely, research, and production and development services relating to bio-technology and science, namely, G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical research and development; Scientific and technological services, namely, biological and bio-technology analysis services; scientific and medical laboratory services; biochemistry research services, namely, treating therapeutic targets through chemical and biochemical preparations | ACTIVE | — |
| 044 | Providing a website featuring information about the treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Septerna, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named GPCR NATIVE COMPLEX
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 21, 2023 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 20, 2023 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 20, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 20, 2023 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jul 20, 2023 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| May 1, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 1, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 1, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 15, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 13, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 13, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 13, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 13, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 13, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 3, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 3, 2021 | NWAP | NEW APPLICATION ENTERED | — |